Preliminary in-vitro evaluation of marketed formulations for antacid activity

Simple item page
dc.contributor.authorDhawal, Pranjali P.en_US
dc.contributor.authorBarve, Siddhivinayak S.en_US
dc.date.accessioned2020-04-23T08:00:02Z
dc.date.available2020-04-23T08:00:02Z
dc.date.issued2020-01
dc.description.abstractBackground: Hydrochloric acid (pH 1.5-3.5) being the major component of gastric acid is produced by parietal cells of stomach. Its secretion is a complex and relatively energetically expensive process. The preservation of acidity of stomach is evidently important because of its implications in peptic and duodenal ulceration.Methods: In the present study, we attempted to compare the activity of 13 (F1-F13) antacid formulations (5-liquid, 4- quick releases and 4- tablets) by using acid-base neutralization studies. Preliminary antacid test (PAT) was performed to define whether the given formulation falls under the category of antacid wherein the pH of the antacid-acid (HCl) solution should be higher than pH of 3.5. The chosen antacids were further subjected to acid neutralizing capacity (ANC) (reaction between the sample of antacid and amount of acid neutralized by the formulation) and acid neutralizing potential (ANP) which explains the time duration during which a given sample of antacid can maintain pH above 3.5).Results: Out of the 13 samples tested, two formulations of pastels (F6, F12) were rejected as per the standard protocol of classifying formulations as antacids after screening for PAT. Sample F5 was found to have the highest ANC. F7 also showed highest ANC among the tablets tested. Also, F13 showed better ANC and ANP as in comparison to other quick releases.Conclusions: Digene products (F5, F7, and F13) showed better antacid properties. This data would provide insights into development of drug, comparison between antacids depending on their chemical formulation and determination of dosage to avoid plausible side effects.en_US
dc.identifier.affiliationsDepartment of Animal Biotechnology and Biochemistry, KET抯 Scientific Research Centre, Mumbai, Maharashtra, Indiaen_US
dc.identifier.affiliationsKET抯 Scientific Research Centre, Mumbai, Maharashtra, Indiaen_US
dc.identifier.citationDhawal Pranjali P., Barve Siddhivinayak S.. Preliminary in-vitro evaluation of marketed formulations for antacid activity. International Journal of Basic & Clinical Pharmacology. 2020 Jan; 9(1): 57-62en_US
dc.identifier.issn2319-2003
dc.identifier.issn2279-0780
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/200478
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber1en_US
dc.relation.volume9en_US
dc.source.urihttps://dx.doi.org/10.18203/2319-2003.ijbcp20195764en_US
dc.subjectAntaciden_US
dc.subjectANCen_US
dc.subjectANPen_US
dc.subjectPeptic ulcerationen_US
dc.subjectPATen_US
dc.titlePreliminary in-vitro evaluation of marketed formulations for antacid activityen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijbcp2020v9n1p57.pdf
Size:
328.37 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Basic & Clinical Pharmacology